These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 31605245)
21. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors. Chen JA; Ma W; Yuan J; Li T Cancer Treat Res; 2020; 180():251-279. PubMed ID: 32215873 [TBL] [Abstract][Full Text] [Related]
23. [Toxicity of immune checkpoints inhibitors]. Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624 [TBL] [Abstract][Full Text] [Related]
24. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review]. Papouin B; Mussini C; De Martin E; Guettier C Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243 [TBL] [Abstract][Full Text] [Related]
25. Immunological and clinical implications of immune checkpoint blockade in human cancer. Kim HD; Park SH Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer. van Holstein Y; Kapiteijn E; Bastiaannet E; van den Bos F; Portielje J; de Glas NA Drugs Aging; 2019 Oct; 36(10):927-938. PubMed ID: 31317421 [TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. Elia AR; Caputo S; Bellone M Front Immunol; 2018; 9():1786. PubMed ID: 30108594 [TBL] [Abstract][Full Text] [Related]
28. The application of nanotechnology in immune checkpoint blockade for cancer treatment. Deng H; Zhang Z J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266 [TBL] [Abstract][Full Text] [Related]
34. Emerging role of checkpoint inhibition in localized bladder cancer. Singh P; Black P Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977 [TBL] [Abstract][Full Text] [Related]
35. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
36. Role of immune-checkpoint inhibitors in lung cancer. Jain P; Jain C; Velcheti V Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894 [TBL] [Abstract][Full Text] [Related]
37. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis. Xu M; Nie Y; Yang Y; Lu YT; Su Q Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716 [TBL] [Abstract][Full Text] [Related]
38. Radiotherapy in combination with immune checkpoint inhibitors. De Ruysscher D; Reynders K; Van Limbergen E; Lambrecht M Curr Opin Oncol; 2017 Mar; 29(2):105-111. PubMed ID: 28085679 [TBL] [Abstract][Full Text] [Related]
39. Hypofractionated radiation therapy with versus without immune checkpoint inhibitors in patients with brain metastases: A meta-analysis. Yang L; Liu L; Wu X; Guo X; Yang Y; Wang T Int Immunopharmacol; 2020 Mar; 80():106148. PubMed ID: 31978802 [TBL] [Abstract][Full Text] [Related]
40. Checkpoint Inhibitor-Induced Rejection of a Liver Allograft: A Combination of Acute T Cell-Mediated and Antibody-Mediated Rejection. Lee BT; Horwich BH; Chopra S; Ahearn A; Han HH Liver Transpl; 2019 Dec; 25(12):1845-1848. PubMed ID: 31408574 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]